Sucampo Pharmaceuticals Submits Supplemental New Drug Application For Lubiprostone To Treat Irritable Bowel Syndrome With Constipation
Sucampo Pharmaceuticals, Inc., (Sucampo Pharmaceuticals) today announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).
